Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.32 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 2/20 | 0.31 |
| ▸ | GHSR | Q92847 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612231 | 0.93 | F11 (0.31) | CYP2D6F11MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3613020 | 0.92 | CYP2D6 (0.32) | CYP2D6F11 | |
| SCHEMBL3603775 | 0.86 | GHSR (0.33) | CYP2D6SOAT2ACAT1SOAT1F11 | |
| SCHEMBL3614774 | 0.86 | GHSR (0.35) | CYP2D6SOAT2ACAT1SOAT1F11 | |
| Hydrochloric Acid SCHEMBL3608122 | 0.85 | GHSR (0.32) | CYP2D6F11GHSRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3611582 | 0.84 | DRD2 (0.35) | CYP2D6PPARGPPARDPPARA | |
| Hydrochloric Acid SCHEMBL3605870 | 0.84 | GHSR (0.35) | CYP2D6SOAT2ACAT1SOAT1F11 | |
| SCHEMBL3617850 | 0.84 | PPARG (0.33) | F11MEN1KMT2APPARGPPARD | |
| SCHEMBL3617998 | 0.83 | PPARG (0.33) | F11MEN1KMT2APPARGPPARD | |
| SCHEMBL3610348 | 0.83 | GHSR (0.33) | F11GHSRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | CYP2D6 615/4885SOAT2 7/4885ACAT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.